Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway

Ming Hsien Chien, Chia Chi Ku, Gunnar Johansson, Min Wei Chen, Michael Hsiao, Jen Liang Su, Hiroyasu Inoue, Kuo Tai Hua, Lin Hung Wei, Min Liang Kuo

研究成果: 雜誌貢獻文章

63 引文 (Scopus)

摘要

Vascular endothelial growth factor (VEGF)-C is recognized as a tumor lymphangiogenic factor based on the effects of activated VEGF-R3 on lymphatic endothelial cells. Many tumor cells express VEGF-R3 but the function of this receptor in tumor cells is largely unknown. It has been reported that the VEGF-C/VEGF-R3 axis is activated in subsets of leukemia patients. Herein, we have shown that VEGF-C induces angiogenic activity in the tube formation assay . invitro and Matrigel plug assay . in vivo by upregulating an angiogenic factor, cyclooxygenase-2 (COX-2), through VEGF-R3 in the human acute myeloid leukemia (AML) cell line, THP-1. COX-2 induction by VEGF-C was also observed in other VEGF-R3. + human AML cell lines (U937 and HL60). Moreover, immunohistochemical analysis of bone marrow specimens of 37 patients diagnosed with AML revealed that VEGF-C expression in specimens was associated with the expression of COX-2 (. P <0.001). The manner by which signaling pathways transduced by VEGF-C is responsible for COX-2 upregulation was further investigated. Blocking the p42/44 mitogen-activated protein kinase (MAPK) pathway with the MAPK kinase inhibitor, PD 98059, failed to inhibit VEGF-C-mediated COX-2 expression. However, VEGF-C-induced COX-2 upregulation was effectively abolished by overexpression of dominant-negative c-Jun N-terminal kinase (JNK) or treatment with the JNK inhibitor, SP 600125. VEGF-C induced JNK-dependent nuclear translocation of c-Jun. Furthermore, chromatin immunoprecipitation and reporter assays revealed that VEGF-C enhanced c-Jun binding to the cyclic adenosine 3',5'-monophosphate-response element of the COX-2 promoter and induced COX-2 expression. In sum, the data herein highlight the pathogenic role of VEGF-C in leukemia via regulation of angiogenesis through upregulation of COX-2.

原文英語
頁(從 - 到)2005-2013
頁數9
期刊Carcinogenesis
30
發行號12
DOIs
出版狀態已發佈 - 十月 13 2009

指紋

Vascular Endothelial Growth Factor C
Transcription Factor AP-1
Cyclooxygenase 2
Vascular Endothelial Growth Factor A
Phosphotransferases
Acute Myeloid Leukemia
Up-Regulation
Myeloid Cells
Leukemia
Cell Line
Neoplasms
JNK Mitogen-Activated Protein Kinases
Angiogenesis Inducing Agents
Chromatin Immunoprecipitation
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase Kinases
Response Elements
Cyclic AMP
Endothelial Cells
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research

引用此文

Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. / Chien, Ming Hsien; Ku, Chia Chi; Johansson, Gunnar; Chen, Min Wei; Hsiao, Michael; Su, Jen Liang; Inoue, Hiroyasu; Hua, Kuo Tai; Wei, Lin Hung; Kuo, Min Liang.

於: Carcinogenesis, 卷 30, 編號 12, 13.10.2009, p. 2005-2013.

研究成果: 雜誌貢獻文章

Chien, MH, Ku, CC, Johansson, G, Chen, MW, Hsiao, M, Su, JL, Inoue, H, Hua, KT, Wei, LH & Kuo, ML 2009, 'Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway', Carcinogenesis, 卷 30, 編號 12, 頁 2005-2013. https://doi.org/10.1093/carcin/bgp244
Chien, Ming Hsien ; Ku, Chia Chi ; Johansson, Gunnar ; Chen, Min Wei ; Hsiao, Michael ; Su, Jen Liang ; Inoue, Hiroyasu ; Hua, Kuo Tai ; Wei, Lin Hung ; Kuo, Min Liang. / Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. 於: Carcinogenesis. 2009 ; 卷 30, 編號 12. 頁 2005-2013.
@article{6ca0368a8b664bd6bd75b476d48cb494,
title = "Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway",
abstract = "Vascular endothelial growth factor (VEGF)-C is recognized as a tumor lymphangiogenic factor based on the effects of activated VEGF-R3 on lymphatic endothelial cells. Many tumor cells express VEGF-R3 but the function of this receptor in tumor cells is largely unknown. It has been reported that the VEGF-C/VEGF-R3 axis is activated in subsets of leukemia patients. Herein, we have shown that VEGF-C induces angiogenic activity in the tube formation assay . invitro and Matrigel plug assay . in vivo by upregulating an angiogenic factor, cyclooxygenase-2 (COX-2), through VEGF-R3 in the human acute myeloid leukemia (AML) cell line, THP-1. COX-2 induction by VEGF-C was also observed in other VEGF-R3. + human AML cell lines (U937 and HL60). Moreover, immunohistochemical analysis of bone marrow specimens of 37 patients diagnosed with AML revealed that VEGF-C expression in specimens was associated with the expression of COX-2 (. P <0.001). The manner by which signaling pathways transduced by VEGF-C is responsible for COX-2 upregulation was further investigated. Blocking the p42/44 mitogen-activated protein kinase (MAPK) pathway with the MAPK kinase inhibitor, PD 98059, failed to inhibit VEGF-C-mediated COX-2 expression. However, VEGF-C-induced COX-2 upregulation was effectively abolished by overexpression of dominant-negative c-Jun N-terminal kinase (JNK) or treatment with the JNK inhibitor, SP 600125. VEGF-C induced JNK-dependent nuclear translocation of c-Jun. Furthermore, chromatin immunoprecipitation and reporter assays revealed that VEGF-C enhanced c-Jun binding to the cyclic adenosine 3',5'-monophosphate-response element of the COX-2 promoter and induced COX-2 expression. In sum, the data herein highlight the pathogenic role of VEGF-C in leukemia via regulation of angiogenesis through upregulation of COX-2.",
author = "Chien, {Ming Hsien} and Ku, {Chia Chi} and Gunnar Johansson and Chen, {Min Wei} and Michael Hsiao and Su, {Jen Liang} and Hiroyasu Inoue and Hua, {Kuo Tai} and Wei, {Lin Hung} and Kuo, {Min Liang}",
year = "2009",
month = "10",
day = "13",
doi = "10.1093/carcin/bgp244",
language = "English",
volume = "30",
pages = "2005--2013",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway

AU - Chien, Ming Hsien

AU - Ku, Chia Chi

AU - Johansson, Gunnar

AU - Chen, Min Wei

AU - Hsiao, Michael

AU - Su, Jen Liang

AU - Inoue, Hiroyasu

AU - Hua, Kuo Tai

AU - Wei, Lin Hung

AU - Kuo, Min Liang

PY - 2009/10/13

Y1 - 2009/10/13

N2 - Vascular endothelial growth factor (VEGF)-C is recognized as a tumor lymphangiogenic factor based on the effects of activated VEGF-R3 on lymphatic endothelial cells. Many tumor cells express VEGF-R3 but the function of this receptor in tumor cells is largely unknown. It has been reported that the VEGF-C/VEGF-R3 axis is activated in subsets of leukemia patients. Herein, we have shown that VEGF-C induces angiogenic activity in the tube formation assay . invitro and Matrigel plug assay . in vivo by upregulating an angiogenic factor, cyclooxygenase-2 (COX-2), through VEGF-R3 in the human acute myeloid leukemia (AML) cell line, THP-1. COX-2 induction by VEGF-C was also observed in other VEGF-R3. + human AML cell lines (U937 and HL60). Moreover, immunohistochemical analysis of bone marrow specimens of 37 patients diagnosed with AML revealed that VEGF-C expression in specimens was associated with the expression of COX-2 (. P <0.001). The manner by which signaling pathways transduced by VEGF-C is responsible for COX-2 upregulation was further investigated. Blocking the p42/44 mitogen-activated protein kinase (MAPK) pathway with the MAPK kinase inhibitor, PD 98059, failed to inhibit VEGF-C-mediated COX-2 expression. However, VEGF-C-induced COX-2 upregulation was effectively abolished by overexpression of dominant-negative c-Jun N-terminal kinase (JNK) or treatment with the JNK inhibitor, SP 600125. VEGF-C induced JNK-dependent nuclear translocation of c-Jun. Furthermore, chromatin immunoprecipitation and reporter assays revealed that VEGF-C enhanced c-Jun binding to the cyclic adenosine 3',5'-monophosphate-response element of the COX-2 promoter and induced COX-2 expression. In sum, the data herein highlight the pathogenic role of VEGF-C in leukemia via regulation of angiogenesis through upregulation of COX-2.

AB - Vascular endothelial growth factor (VEGF)-C is recognized as a tumor lymphangiogenic factor based on the effects of activated VEGF-R3 on lymphatic endothelial cells. Many tumor cells express VEGF-R3 but the function of this receptor in tumor cells is largely unknown. It has been reported that the VEGF-C/VEGF-R3 axis is activated in subsets of leukemia patients. Herein, we have shown that VEGF-C induces angiogenic activity in the tube formation assay . invitro and Matrigel plug assay . in vivo by upregulating an angiogenic factor, cyclooxygenase-2 (COX-2), through VEGF-R3 in the human acute myeloid leukemia (AML) cell line, THP-1. COX-2 induction by VEGF-C was also observed in other VEGF-R3. + human AML cell lines (U937 and HL60). Moreover, immunohistochemical analysis of bone marrow specimens of 37 patients diagnosed with AML revealed that VEGF-C expression in specimens was associated with the expression of COX-2 (. P <0.001). The manner by which signaling pathways transduced by VEGF-C is responsible for COX-2 upregulation was further investigated. Blocking the p42/44 mitogen-activated protein kinase (MAPK) pathway with the MAPK kinase inhibitor, PD 98059, failed to inhibit VEGF-C-mediated COX-2 expression. However, VEGF-C-induced COX-2 upregulation was effectively abolished by overexpression of dominant-negative c-Jun N-terminal kinase (JNK) or treatment with the JNK inhibitor, SP 600125. VEGF-C induced JNK-dependent nuclear translocation of c-Jun. Furthermore, chromatin immunoprecipitation and reporter assays revealed that VEGF-C enhanced c-Jun binding to the cyclic adenosine 3',5'-monophosphate-response element of the COX-2 promoter and induced COX-2 expression. In sum, the data herein highlight the pathogenic role of VEGF-C in leukemia via regulation of angiogenesis through upregulation of COX-2.

UR - http://www.scopus.com/inward/record.url?scp=73949133917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949133917&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgp244

DO - 10.1093/carcin/bgp244

M3 - Article

C2 - 19825968

AN - SCOPUS:73949133917

VL - 30

SP - 2005

EP - 2013

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 12

ER -